1
|
Henno P, Maurey C, Le Pimpec-Barthes F, Devillier P, Delclaux C, Israël-Biet D. Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction? Respir Res 2015; 16:46. [PMID: 25889611 PMCID: PMC4391310 DOI: 10.1186/s12931-015-0196-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Accepted: 02/25/2015] [Indexed: 11/29/2022] Open
Abstract
Background Tobacco-induced pulmonary vascular disease is partly driven by endothelial dysfunction. The bioavailability of the potent vasodilator nitric oxide (NO) depends on competition between NO synthase-3 (NOS3) and arginases for their common substrate (L-arginine). We tested the hypothesis whereby tobacco smoking impairs pulmonary endothelial function via upregulation of the arginase pathway. Methods Endothelium-dependent vasodilation in response to acetylcholine (Ach) was compared ex vivo for pulmonary vascular rings from 29 smokers and 10 never-smokers. The results were expressed as a percentage of the contraction with phenylephrine. We tested the effects of L-arginine supplementation, arginase inhibition (by N(omega)-hydroxy-nor-l-arginine, NorNOHA) and NOS3 induction (by genistein) on vasodilation. Protein levels of NOS3 and arginases I and II in the pulmonary arteries were quantified by Western blotting. Results Overall, vasodilation was impaired in smokers (relative to controls; p < 0.01). Eleven of the 29 smokers (the ED+ subgroup) displayed endothelial dysfunction (defined as the absence of a relaxant response to Ach), whereas 18 (the ED− subgroup) had normal vasodilation. The mean responses to 10−4 M Ach were −23 ± 10% and 31 ± 4% in the ED+ and ED− subgroups, respectively (p < 0.01). Supplementation with L- arginine improved endothelial function in the ED+ subgroup (−4 ± 10% vs. -32 ± 10% in the presence and absence of L- arginine, respectively; p = 0.006), as did arginase inhibition (18 ± 9% vs. -1 ± 9%, respectively; p = 0.0002). Arginase I protein was overexpressed in ED+ samples, whereas ED+ and ED− samples did not differ significantly in terms of NOS3 expression. Treatment with genistein did not significantly improve endothelial function in ED+ samples. Conclusion Overexpression and elevated activity of arginase I are involved in tobacco-induced pulmonary endothelial dysfunction.
Collapse
Affiliation(s)
- Priscilla Henno
- Sorbonne Universités, UPMC Université Paris 06, Paris, France. .,Département Physiologie-Algologie-Somnologie, Unité Fonctionnelle de Somnologie et Fonction Respiratoire, AP-HP, Hôpital Saint Antoine, 75012, Paris, France. .,Laboratoire de Pharmacologie Respiratoire UPRES EA 220, Hôpital Foch, 92150, Suresnes, France.
| | - Christelle Maurey
- Ecole Nationale Vétérinaire d'Alfort, Unité de Médecine, Université Paris-Est, 94700, Maisons-Alfort, France.
| | - Françoise Le Pimpec-Barthes
- Sorbonne Paris Cité, Université Paris-Descartes, Paris, France. .,Service de Chirurgie Thoracique, AP-HP, Hôpital Européen Georges Pompidou, 75015, Paris, France.
| | - Philippe Devillier
- Laboratoire de Pharmacologie Respiratoire UPRES EA 220, Hôpital Foch, 92150, Suresnes, France. .,Université Versailles Saint-Quentin en Yvelines, UFR Sciences de la Santé Simone Veil, Montigny le Bretonneux, France.
| | - Christophe Delclaux
- Sorbonne Paris Cité, Université Paris-Descartes, Paris, France. .,Service de Physiologie, Explorations Fonctionnelles Respiratoires et du Sommeil, AP-HP, Hôpital Européen Georges Pompidou, 75015, Paris, France.
| | - Dominique Israël-Biet
- Sorbonne Paris Cité, Université Paris-Descartes, Paris, France. .,Service de Pneumologie, AP-HP, Hôpital Européen Georges Pompidou, 75015, Paris, France.
| |
Collapse
|